Trial Profile
A Randomised, Open-label, Multi-centre Trial Investigating the Intra-subject Variability of ROTEM and TEG Parameters Following Two Intravenous Administrations of the Same Dose of Activated Recombinant Factor VII (rFVIIa/NovoSeven) in Haemophilia Patients in a Non-bleeding State
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 13 Apr 2015 New trial record